Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rifaximin-α prophylaxis in cirrhosis: gut microbiome and resistome study
ChiCTR1900022234Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rifaximin in hepatic encephalopathy (HE), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Gut microbial diversity and Bacterial resistance / intestinal resistome. Started Mar 2018; status: recruiting.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on ChiCTR1900022234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022234.